News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Stemline Therapeutics, Inc. Postpones IPO



8/9/2012 7:39:50 AM

Stemline Therapeutics, a biotech developing treatments that target cancer stem cells and tumor bulk, postponed its IPO on Tuesday. The New York, NY-based company had been planning to raise $42 million at a price range of $11 to $13. RBC Capital Markets, Oppenheimer & Co. were set to be the joint bookrunners on the deal.

Read at Nasdaq
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES